Results with Optilume consistent in clinical trials and real world, regardless of prostate ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch well beyond its original purpose? That’s exactly the twist happening with a ...

In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

As men age, their bodies go through many natural changes. One such change, often less spoken about, is the enlargement of the ...

Prodeon Medical’s Urocross Expander System receives US FDA 510(k) clearance for treating urinary symptoms associated with benign prostatic hyperplasia: Sunnyvale, California Thu ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

EDAP management highlighted what it sees as a growing global opportunity for therapeutic ultrasound in urology, emphasizing the company’s Focal One robotic high-intensity focused ultrasound (HIFU) ...

A prescription medication that has been available in the U.S. since 1992 might have another significant benefit.

Cesar Chavez’s influence on Kern County and the nation has long been cemented through major recognitions and historic sites ...

HKSH Medical Group (HKSH) today announced the results of Asia's first clinical study on early-stage prostate cancer patients receiving five-session of proton therapy.* The results show significant ...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...